Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Inclusion Criteria:

• Histologically confirmed advanced malignancy (solid tumor or lymphoma) that ismetastatic or unresectable for which standard curative measures do not exist or are nolonger effective

• Eastern Cooperative Oncology Group (ECOG) performance status </= 2

• Life expectancy greater than 3 months

• Adequate organ and marrow function

• Written informed consent

• Use of acceptable methods of contraception during the course of the study and for 3months after completion of study

• In the MTD expanded cohort: at least 20 subjects with metastatic and/oradvanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgicalresection with measurable disease as defined by RECIST

Exclusion Criteria:

• Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycinC within 6 weeks) before the first scheduled dose of XL184

• Administration of an investigational drug within 30 days of the first dose of XL184

• Subject has not recovered from adverse events due to investigational agents or othermedications administered more than 4 weeks before study enrollment

• Known brain metastases

• Uncontrolled intercurrent illness

• Pregnancy or breastfeeding

• Known HIV positive

• Known allergy or hypersensitivity to any of the components of the XL184 formulation